The estimated Net Worth of Richard M Marsh is at least $5.92 million dollars as of 11 July 2018. Richard Marsh owns over 70,672 units of Myriad Genetics stock worth over $4,315,097 and over the last 21 years Richard sold MYGN stock worth over $1,606,624.
Richard has made over 46 trades of the Myriad Genetics stock since 2005, according to the Form 4 filled with the SEC. Most recently Richard exercised 70,672 units of MYGN stock worth $1,633,230 on 11 July 2018.
The largest trade Richard's ever made was exercising 70,672 units of Myriad Genetics stock on 11 July 2018 worth over $1,633,230. On average, Richard trades about 11,854 units every 60 days since 2003. As of 11 July 2018 Richard still owns at least 164,197 units of Myriad Genetics stock.
You can see the complete history of Richard Marsh stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is 5781 MEADOW CREST, , MURRAY, UT, 84107.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum et Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: